Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Respiratory Tract Infections | 13 | 2018 | 437 | 2.500 |
Why?
|
Respiratory Syncytial Virus Infections | 14 | 2021 | 427 | 2.150 |
Why?
|
Antiviral Agents | 19 | 2020 | 1234 | 1.560 |
Why?
|
Ribavirin | 8 | 2018 | 178 | 1.360 |
Why?
|
Hematopoietic Stem Cell Transplantation | 23 | 2021 | 6607 | 1.290 |
Why?
|
Paramyxoviridae Infections | 4 | 2017 | 86 | 1.210 |
Why?
|
Respiratory Syncytial Virus, Human | 7 | 2021 | 211 | 1.100 |
Why?
|
Aerosols | 4 | 2013 | 158 | 1.080 |
Why?
|
Hematologic Neoplasms | 8 | 2018 | 1901 | 1.020 |
Why?
|
Influenza, Human | 6 | 2017 | 924 | 0.860 |
Why?
|
Transplant Recipients | 7 | 2021 | 322 | 0.790 |
Why?
|
Hepatitis B Vaccines | 4 | 2015 | 51 | 0.760 |
Why?
|
Neoplasms | 22 | 2023 | 15180 | 0.750 |
Why?
|
Vaccines, Synthetic | 1 | 2021 | 356 | 0.700 |
Why?
|
Cytomegalovirus Infections | 6 | 2020 | 454 | 0.700 |
Why?
|
Feces | 2 | 2021 | 772 | 0.650 |
Why?
|
Hepatitis B | 4 | 2015 | 259 | 0.630 |
Why?
|
Bacteria | 2 | 2021 | 611 | 0.610 |
Why?
|
Metapneumovirus | 2 | 2017 | 58 | 0.570 |
Why?
|
Drug Users | 2 | 2015 | 18 | 0.550 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 711 | 0.540 |
Why?
|
Immunization Schedule | 2 | 2015 | 114 | 0.530 |
Why?
|
Immunologic Deficiency Syndromes | 2 | 2015 | 240 | 0.520 |
Why?
|
Hepacivirus | 2 | 2012 | 398 | 0.420 |
Why?
|
Respiratory Syncytial Viruses | 3 | 2019 | 171 | 0.420 |
Why?
|
Energy Metabolism | 1 | 2018 | 994 | 0.420 |
Why?
|
Viral Load | 3 | 2019 | 492 | 0.420 |
Why?
|
Occupational Exposure | 2 | 2014 | 248 | 0.400 |
Why?
|
Antibodies, Viral | 6 | 2021 | 1317 | 0.400 |
Why?
|
Middle Aged | 36 | 2023 | 86544 | 0.370 |
Why?
|
Gastrointestinal Microbiome | 2 | 2021 | 907 | 0.370 |
Why?
|
Pandemics | 4 | 2022 | 1564 | 0.370 |
Why?
|
Transplantation Conditioning | 2 | 2018 | 2286 | 0.370 |
Why?
|
Cohort Studies | 11 | 2023 | 9282 | 0.360 |
Why?
|
Viral Fusion Proteins | 3 | 2020 | 85 | 0.350 |
Why?
|
Aged | 33 | 2023 | 70367 | 0.350 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2012 | 242 | 0.350 |
Why?
|
Accidents, Occupational | 1 | 2009 | 12 | 0.340 |
Why?
|
Cytomegalovirus | 5 | 2020 | 474 | 0.340 |
Why?
|
Hand Injuries | 1 | 2009 | 18 | 0.340 |
Why?
|
Agriculture | 1 | 2009 | 40 | 0.340 |
Why?
|
Transients and Migrants | 1 | 2009 | 27 | 0.340 |
Why?
|
Male | 42 | 2023 | 123338 | 0.320 |
Why?
|
Drug Resistance, Viral | 3 | 2016 | 71 | 0.310 |
Why?
|
Venous Thromboembolism | 2 | 2023 | 336 | 0.310 |
Why?
|
Enzyme-Linked Immunospot Assay | 2 | 2019 | 33 | 0.300 |
Why?
|
Lung | 1 | 2018 | 3167 | 0.300 |
Why?
|
Female | 40 | 2023 | 142293 | 0.300 |
Why?
|
Humans | 59 | 2023 | 262248 | 0.300 |
Why?
|
Host-Pathogen Interactions | 2 | 2021 | 315 | 0.300 |
Why?
|
Incidence | 6 | 2019 | 5713 | 0.290 |
Why?
|
Hepatitis C, Chronic | 1 | 2012 | 451 | 0.280 |
Why?
|
Young Adult | 14 | 2018 | 21494 | 0.270 |
Why?
|
Immunocompromised Host | 4 | 2018 | 697 | 0.260 |
Why?
|
Risk Factors | 12 | 2022 | 17622 | 0.250 |
Why?
|
Prostatic Neoplasms | 2 | 2019 | 5778 | 0.250 |
Why?
|
Adult | 24 | 2023 | 78179 | 0.240 |
Why?
|
Adolescent | 15 | 2023 | 31239 | 0.240 |
Why?
|
Healthcare Disparities | 2 | 2020 | 600 | 0.240 |
Why?
|
RNA, Ribosomal, 16S | 3 | 2021 | 486 | 0.230 |
Why?
|
Retrospective Studies | 18 | 2023 | 38011 | 0.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2015 | 1219 | 0.220 |
Why?
|
Antibodies, Neutralizing | 4 | 2021 | 545 | 0.220 |
Why?
|
Cross Infection | 3 | 2017 | 543 | 0.210 |
Why?
|
Coronavirus Infections | 2 | 2020 | 647 | 0.210 |
Why?
|
Rural Population | 2 | 2022 | 281 | 0.200 |
Why?
|
Seroconversion | 1 | 2021 | 19 | 0.200 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 128 | 0.200 |
Why?
|
Viral Structural Proteins | 1 | 2021 | 47 | 0.200 |
Why?
|
Gloves, Surgical | 1 | 2021 | 10 | 0.200 |
Why?
|
Child, Preschool | 8 | 2017 | 16213 | 0.190 |
Why?
|
Antigens, Viral | 2 | 2020 | 467 | 0.190 |
Why?
|
Immunity, Mucosal | 1 | 2021 | 110 | 0.190 |
Why?
|
Immunity, Humoral | 1 | 2021 | 86 | 0.190 |
Why?
|
Palivizumab | 2 | 2018 | 64 | 0.190 |
Why?
|
Liver Diseases | 2 | 2019 | 570 | 0.190 |
Why?
|
Vaccination | 3 | 2016 | 1125 | 0.190 |
Why?
|
Urban Population | 1 | 2022 | 269 | 0.190 |
Why?
|
Influenza Vaccines | 2 | 2016 | 635 | 0.180 |
Why?
|
Health Personnel | 2 | 2016 | 632 | 0.180 |
Why?
|
Stomatitis | 1 | 2020 | 183 | 0.170 |
Why?
|
Breast Neoplasms | 1 | 2023 | 15709 | 0.170 |
Why?
|
Drug Utilization | 1 | 2020 | 180 | 0.170 |
Why?
|
Immunity | 1 | 2021 | 346 | 0.170 |
Why?
|
Specimen Handling | 1 | 2021 | 299 | 0.170 |
Why?
|
Texas | 4 | 2015 | 6308 | 0.160 |
Why?
|
Rubulavirus | 1 | 2018 | 8 | 0.160 |
Why?
|
Respiratory Mucosa | 1 | 2020 | 206 | 0.160 |
Why?
|
Viral Envelope Proteins | 1 | 2020 | 207 | 0.160 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 4903 | 0.160 |
Why?
|
Virus Activation | 2 | 2019 | 228 | 0.160 |
Why?
|
Rectum | 1 | 2021 | 469 | 0.160 |
Why?
|
Leukopenia | 1 | 2018 | 151 | 0.160 |
Why?
|
Ribotyping | 1 | 2018 | 48 | 0.160 |
Why?
|
Administration, Inhalation | 3 | 2014 | 286 | 0.160 |
Why?
|
Substance-Related Disorders | 2 | 2014 | 530 | 0.150 |
Why?
|
United States | 5 | 2023 | 15574 | 0.150 |
Why?
|
Hypoxia | 2 | 2017 | 448 | 0.150 |
Why?
|
Child | 8 | 2017 | 29067 | 0.150 |
Why?
|
Odds Ratio | 4 | 2022 | 2325 | 0.150 |
Why?
|
Mexico | 1 | 2017 | 257 | 0.150 |
Why?
|
Serum Albumin | 1 | 2017 | 251 | 0.140 |
Why?
|
Organophosphonates | 1 | 2016 | 64 | 0.140 |
Why?
|
Isoxazoles | 1 | 2016 | 81 | 0.140 |
Why?
|
Prospective Studies | 6 | 2023 | 12923 | 0.140 |
Why?
|
Logistic Models | 3 | 2019 | 3450 | 0.130 |
Why?
|
Lymphocyte Transfusion | 1 | 2016 | 178 | 0.130 |
Why?
|
Cytosine | 1 | 2016 | 141 | 0.130 |
Why?
|
Coinfection | 1 | 2017 | 189 | 0.130 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 180 | 0.130 |
Why?
|
Herpesviridae Infections | 1 | 2016 | 174 | 0.130 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2015 | 152 | 0.130 |
Why?
|
Herbaspirillum | 1 | 2014 | 6 | 0.130 |
Why?
|
Pharmacogenetics | 1 | 2016 | 253 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2019 | 661 | 0.120 |
Why?
|
Interferon-gamma Release Tests | 1 | 2016 | 87 | 0.120 |
Why?
|
Aged, 80 and over | 8 | 2021 | 29996 | 0.120 |
Why?
|
Community-Acquired Infections | 1 | 2017 | 285 | 0.120 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1363 | 0.120 |
Why?
|
Microbiota | 1 | 2020 | 543 | 0.120 |
Why?
|
Blood | 1 | 2014 | 156 | 0.120 |
Why?
|
Central Venous Catheters | 1 | 2014 | 98 | 0.110 |
Why?
|
Genotype | 3 | 2016 | 4104 | 0.110 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2014 | 158 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2021 | 3755 | 0.110 |
Why?
|
Transplantation | 1 | 2013 | 56 | 0.110 |
Why?
|
Infant | 4 | 2017 | 13285 | 0.110 |
Why?
|
Treatment Outcome | 7 | 2020 | 33028 | 0.110 |
Why?
|
Up-Regulation | 1 | 2019 | 2450 | 0.110 |
Why?
|
Cause of Death | 3 | 2022 | 757 | 0.110 |
Why?
|
Hepatitis C Antibodies | 1 | 2012 | 41 | 0.100 |
Why?
|
Behavior | 1 | 2012 | 102 | 0.100 |
Why?
|
Catheter-Related Infections | 1 | 2014 | 269 | 0.100 |
Why?
|
Survival Analysis | 2 | 2013 | 9195 | 0.100 |
Why?
|
Virus Diseases | 1 | 2014 | 399 | 0.090 |
Why?
|
Case-Control Studies | 2 | 2018 | 6104 | 0.090 |
Why?
|
Demography | 1 | 2012 | 438 | 0.090 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 32 | 0.090 |
Why?
|
Immunologic Memory | 1 | 2012 | 374 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2015 | 588 | 0.090 |
Why?
|
Regression Analysis | 2 | 2014 | 1554 | 0.090 |
Why?
|
Practice Patterns, Physicians' | 2 | 2015 | 1305 | 0.090 |
Why?
|
Vaccines | 1 | 2014 | 392 | 0.090 |
Why?
|
Comorbidity | 3 | 2021 | 2397 | 0.090 |
Why?
|
RNA, Viral | 1 | 2012 | 667 | 0.080 |
Why?
|
Virus Shedding | 2 | 2020 | 88 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 2420 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 1359 | 0.080 |
Why?
|
Survival Rate | 2 | 2018 | 12239 | 0.080 |
Why?
|
Upper Extremity | 1 | 2009 | 87 | 0.080 |
Why?
|
DNA, Ribosomal | 2 | 2021 | 103 | 0.080 |
Why?
|
Drug Therapy, Combination | 3 | 2020 | 2325 | 0.080 |
Why?
|
Immunity, Cellular | 2 | 2020 | 419 | 0.080 |
Why?
|
Hepatitis C | 1 | 2012 | 524 | 0.070 |
Why?
|
T-Lymphocytes | 2 | 2016 | 3879 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2028 | 0.070 |
Why?
|
Immunoglobulin G | 2 | 2021 | 1030 | 0.070 |
Why?
|
Prevalence | 2 | 2016 | 3272 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 1367 | 0.070 |
Why?
|
Surveys and Questionnaires | 2 | 2015 | 5724 | 0.070 |
Why?
|
DNA, Bacterial | 2 | 2021 | 559 | 0.070 |
Why?
|
Allografts | 2 | 2019 | 656 | 0.060 |
Why?
|
Population Surveillance | 1 | 2009 | 628 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 3975 | 0.060 |
Why?
|
Betacoronavirus | 2 | 2020 | 524 | 0.060 |
Why?
|
Risk | 1 | 2009 | 1974 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 4337 | 0.060 |
Why?
|
Hepatitis B Antibodies | 2 | 2014 | 58 | 0.060 |
Why?
|
Interferon-gamma | 2 | 2019 | 1148 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 6900 | 0.050 |
Why?
|
Observational Studies as Topic | 1 | 2023 | 143 | 0.050 |
Why?
|
Prognosis | 2 | 2020 | 21737 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 19 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4563 | 0.050 |
Why?
|
HIV Infections | 1 | 2014 | 2138 | 0.050 |
Why?
|
Spatial Analysis | 1 | 2022 | 35 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2021 | 1958 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 544 | 0.050 |
Why?
|
Health Facilities | 1 | 2022 | 80 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 4027 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2018 | 2892 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2022 | 4355 | 0.050 |
Why?
|
Immunoglobulin A | 1 | 2021 | 241 | 0.050 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 76 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2021 | 2480 | 0.050 |
Why?
|
Immunoglobulin Idiotypes | 1 | 2020 | 51 | 0.050 |
Why?
|
Antibody Formation | 1 | 2021 | 383 | 0.050 |
Why?
|
Antibody Affinity | 1 | 2020 | 61 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2019 | 10348 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 78 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 239 | 0.040 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2019 | 38 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2012 | 8225 | 0.040 |
Why?
|
Public Health | 1 | 2021 | 303 | 0.040 |
Why?
|
Phylogeny | 1 | 2021 | 826 | 0.040 |
Why?
|
Respiration, Artificial | 1 | 2022 | 582 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2018 | 255 | 0.040 |
Why?
|
Anticoagulants | 1 | 2023 | 791 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2023 | 1534 | 0.040 |
Why?
|
Foscarnet | 1 | 2016 | 17 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 720 | 0.040 |
Why?
|
Mutation | 1 | 2016 | 15167 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 526 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2020 | 637 | 0.030 |
Why?
|
Lymphopenia | 1 | 2018 | 199 | 0.030 |
Why?
|
Ganciclovir | 1 | 2016 | 175 | 0.030 |
Why?
|
Organizational Policy | 1 | 2016 | 73 | 0.030 |
Why?
|
Biomarkers | 2 | 2019 | 5055 | 0.030 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2016 | 130 | 0.030 |
Why?
|
Herpes Simplex | 1 | 2016 | 94 | 0.030 |
Why?
|
Time Factors | 2 | 2020 | 12984 | 0.030 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2016 | 182 | 0.030 |
Why?
|
Universal Precautions | 1 | 2014 | 5 | 0.030 |
Why?
|
Bronchoscopy | 1 | 2018 | 475 | 0.030 |
Why?
|
Metformin | 1 | 2019 | 378 | 0.030 |
Why?
|
Betaproteobacteria | 1 | 2014 | 6 | 0.030 |
Why?
|
Burkholderia cepacia | 1 | 2014 | 7 | 0.030 |
Why?
|
Sex Factors | 1 | 2020 | 2156 | 0.030 |
Why?
|
Interferons | 1 | 2016 | 289 | 0.030 |
Why?
|
Protein Conformation | 1 | 2018 | 1257 | 0.030 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2014 | 128 | 0.030 |
Why?
|
Mortality | 1 | 2017 | 346 | 0.030 |
Why?
|
Molecular Typing | 1 | 2014 | 55 | 0.030 |
Why?
|
Epidemiological Monitoring | 1 | 2014 | 73 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2020 | 1308 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2016 | 337 | 0.030 |
Why?
|
Prostatectomy | 1 | 2019 | 963 | 0.030 |
Why?
|
Cancer Survivors | 1 | 2021 | 649 | 0.030 |
Why?
|
Neutropenia | 1 | 2018 | 965 | 0.030 |
Why?
|
Infection Control | 1 | 2016 | 271 | 0.030 |
Why?
|
Registries | 1 | 2022 | 2188 | 0.030 |
Why?
|
Interleukins | 1 | 2016 | 327 | 0.030 |
Why?
|
Viral Proteins | 1 | 2016 | 437 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2015 | 431 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2019 | 876 | 0.030 |
Why?
|
Patient Selection | 1 | 2021 | 2063 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2014 | 302 | 0.030 |
Why?
|
China | 1 | 2014 | 613 | 0.030 |
Why?
|
Databases, Factual | 1 | 2020 | 2236 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2014 | 843 | 0.030 |
Why?
|
Data Collection | 1 | 2014 | 626 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 1054 | 0.030 |
Why?
|
Tissue Donors | 1 | 2016 | 790 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3983 | 0.020 |
Why?
|
Age Factors | 1 | 2020 | 5384 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 548 | 0.020 |
Why?
|
Alleles | 1 | 2016 | 2434 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2017 | 4323 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 3347 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 1557 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2016 | 3891 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2014 | 4231 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2016 | 2059 | 0.020 |
Why?
|
Genetic Testing | 1 | 2016 | 1587 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 928 | 0.020 |
Why?
|
Genetic Variation | 1 | 2016 | 2089 | 0.020 |
Why?
|
Leukemia | 1 | 2016 | 1633 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 6062 | 0.020 |
Why?
|
Disease Progression | 1 | 2018 | 6693 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2012 | 2605 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2020 | 14913 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 4386 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 14561 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 3263 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8882 | 0.010 |
Why?
|